Alena - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

alenami phentermine (as hydrochloride) 40 mg sustained release capsule blister pack

aspen pharmacare australia pty ltd - phentermine hydrochloride, quantity: 49.79 mg (equivalent: phentermine, qty 40 mg) - capsule, modified release - excipient ingredients: lactose monohydrate; sodium polystyrene sulfonate; magnesium stearate; liquid paraffin; titanium dioxide; purified water; sunset yellow fcf; erythrosine; gelatin; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - alenami is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with alenami can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

alenami phentermine (as hydrochloride) 30 mg sustained release capsule blister pack

aspen pharmacare australia pty ltd - phentermine hydrochloride, quantity: 37.34 mg (equivalent: phentermine, qty 30 mg) - capsule, modified release - excipient ingredients: lactose monohydrate; sodium polystyrene sulfonate; magnesium stearate; liquid paraffin; titanium dioxide; purified water; iron oxide red; gelatin; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - alenami is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with alenami can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

alenami phentermine (as hydrochloride) 15 mg sustained release capsule blister pack

aspen pharmacare australia pty ltd - phentermine hydrochloride, quantity: 18.67 mg (equivalent: phentermine, qty 15 mg) - capsule, modified release - excipient ingredients: lactose monohydrate; sodium polystyrene sulfonate; magnesium stearate; liquid paraffin; titanium dioxide; brilliant blue fcf; sunset yellow fcf; purified water; quinoline yellow; gelatin; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - alenami is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with alenami can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.